Рецепт. 2020; : 502-507
Инфекция COVID-19 и реципиенты почечного трансплантата: варианты коррекции иммуносупрессии и лечения
https://doi.org/10.34883/PI.2020.23.4.004Аннотация
В настоящее время отсутствует специфическое лечение инфекции COVID-19, в связи с этим большинство нефрологических обществ считает, что реципиенты с почечным трансплантатом с легкой и средней степенью тяжести течения COVID-19 должны продолжать получать ингибиторы кальциневрина (ИК) и предписанную дозу глюкокортикоидов, но прием антипролиферативных препаратов следует прекратить. В случае тяжелого течения подтвержденного COVID-19, требующего госпитализации в отделение интенсивной терапии и искусственной вентиляции легких, следует немедленно отменить ИК и антипролиферативные препараты, а дозы глюкокортикоидов следует увеличить до 16–20 мг/сутки. В настоящее время неизвестно, следует ли применять антицитокиновые препараты, такие как ингибиторы ИЛ-6 или ингибиторы комплемента, а также отсутствуют результаты единого анализа данных о лечении инфекции COVID-19 у позитивных реципиентов почечного трансплантата с использованием противовирусных лекарственных средств.
Список литературы
1. Sun P., Lu X., Xu C. (2020) Understanding of COVID-19 based on current evidence. J. Med Virol, vol. 92, no 6, pp. 548–551.
2. Yang X., Yu Y., Xu J. (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, vol. 8, no 5, pp. 475–481.
3. Cheng Y., Luo R., Wang K. (2020) Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney International, vol. 97, no 5, pp. 829–838.
4. Kronbichler A., Gauckler P., Windpessl M. (2020) COVID-19: implications for immunosuppression in kidney disease and transplantation. Nat Rev Nephrol, vol. 16, no 7, pp. 365–367.
5. Red Cross media statement on 2019 novel coronavirus. Available at: https://www.redcross.org/about-us/news-and-events/pressrelease/2020/red- cross-media-statement-on-2019-novelcoronavirus. html. Accessed on March 23, 2020.
6. Management of patients on dialysis or with a kidney transplant during COVID-19 infection. By the Brescia Renal COVID-19 Task Force. Available at: https://www.era-edta.org/en/wp-content/uploads/2020/03/COVID_guidelines_finale_eng-GB.pdf.
7. ERA-EDTA WG Descartes expert opinion regarding the management of immunosuppressive medication for kidney transplant patients during the COVID-19 pandemic. Available at: https://www.era-edta.org/en/wp-content/uploads/2020/04/Expert-opinion-on-ISD-in-Covid-19.pdf.
8. Pereira M.R., Mohan S., Cohen D. (2020) COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant, vol. 20, no 7, pp. 1800–1808.
9. Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review.JAMA, vol. 13. doi: 10.1001/jama.2020.6019.
10. Gao J., Tian Z., Yang X. (2020) Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, vol. 14, no 1, pp. 72–73.
11. Magagnoli J., Narendran S., Pereira F. (2020) Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. doi.org/10.1101%2F2020.04.16.20065920.
12. Cao B, Wang Y, Wen D, et al. (2020) A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, vol. 382, no 19, pp. 1787–1799.
13. WHO launches global megatrial of the four most promising coronavirus treatments. Available at: https://www.sciencemag.org/news/2020/03/who- launches-global-megatrial-four-mostpromising-coronavirus-treatments.
Recipe. 2020; : 502-507
Infection COVID-19 and Recipients of Renal Graft:Options of Correction Immunosuppression and Treatment
https://doi.org/10.34883/PI.2020.23.4.004Abstract
References
1. Sun P., Lu X., Xu C. (2020) Understanding of COVID-19 based on current evidence. J. Med Virol, vol. 92, no 6, pp. 548–551.
2. Yang X., Yu Y., Xu J. (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, vol. 8, no 5, pp. 475–481.
3. Cheng Y., Luo R., Wang K. (2020) Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney International, vol. 97, no 5, pp. 829–838.
4. Kronbichler A., Gauckler P., Windpessl M. (2020) COVID-19: implications for immunosuppression in kidney disease and transplantation. Nat Rev Nephrol, vol. 16, no 7, pp. 365–367.
5. Red Cross media statement on 2019 novel coronavirus. Available at: https://www.redcross.org/about-us/news-and-events/pressrelease/2020/red- cross-media-statement-on-2019-novelcoronavirus. html. Accessed on March 23, 2020.
6. Management of patients on dialysis or with a kidney transplant during COVID-19 infection. By the Brescia Renal COVID-19 Task Force. Available at: https://www.era-edta.org/en/wp-content/uploads/2020/03/COVID_guidelines_finale_eng-GB.pdf.
7. ERA-EDTA WG Descartes expert opinion regarding the management of immunosuppressive medication for kidney transplant patients during the COVID-19 pandemic. Available at: https://www.era-edta.org/en/wp-content/uploads/2020/04/Expert-opinion-on-ISD-in-Covid-19.pdf.
8. Pereira M.R., Mohan S., Cohen D. (2020) COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant, vol. 20, no 7, pp. 1800–1808.
9. Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review.JAMA, vol. 13. doi: 10.1001/jama.2020.6019.
10. Gao J., Tian Z., Yang X. (2020) Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, vol. 14, no 1, pp. 72–73.
11. Magagnoli J., Narendran S., Pereira F. (2020) Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. doi.org/10.1101%2F2020.04.16.20065920.
12. Cao B, Wang Y, Wen D, et al. (2020) A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, vol. 382, no 19, pp. 1787–1799.
13. WHO launches global megatrial of the four most promising coronavirus treatments. Available at: https://www.sciencemag.org/news/2020/03/who- launches-global-megatrial-four-mostpromising-coronavirus-treatments.
